Drug Shortage Report for TEVA-RISEDRONATE
Report ID | 216497 |
Drug Identification Number | 02298384 |
Brand name | TEVA-RISEDRONATE |
Common or Proper name | RISEDRONATE 30MG TABL |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | RISEDRONATE SODIUM |
Strength(s) | 30MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30 |
ATC code | M05BA |
ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2024-01-18 |
Estimated end date | Unknown |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2024-01-19 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2024-01-19 | English | Compare |
v2 | 2024-01-18 | French | Compare |
v1 | 2024-01-18 | English | Compare |
Showing 1 to 3 of 3